ICLR ICON PLC
Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1060955
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1.4%
TTM net income YoY5.0%
TTM EPS YoY25.8%
Revenue 3-yr CAGR1.4%
Net income 3-yr CAGR-2.8%
Margins
Gross margin23.5%
Operating margin5.3%
Net margin5.4%
FCF margin10.3%
EBITDA margin9.7%
Returns
ROE5.0%
ROA2.8%
ROIC (approx.)3.0%
Asset turnover0.51x
Leverage & solvency
Liabilities / assets43.8%
Debt / equity0.37x
Current ratio1.32x
Interest coverage2.06x
Cash quality & payout
Operating cash flow / net income2.29x
Accruals ratio-3.6%
Payout ratio—
Capex / revenue2.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $8.25B | $8.19B |
| Cost of revenue | $6.08B | $5.82B |
| Gross profit | $2.18B | $2.37B |
| SG&A expense | $780.14M | $728.35M |
| Operating income | $442.85M | $1.03B |
| Interest expense | $197.49M | $237.24M |
| Pretax income | $252.47M | $803.76M |
| Income tax | $23.13M | $64.63M |
| Net income | $229.34M | $739.13M |
| EBITDA | $825.84M | $1.52B |
| EPS (basic) | 2.92 | 8.96 |
| EPS (diluted) | 2.90 | 8.90 |
| Weighted avg. shares (diluted) | 78.97M | 83.03M |
| Balance sheet | ||
| Cash & equivalents | $647.29M | $538.78M |
| Short-term investments | $0 | $0 |
| Receivables | $1.47B | $1.39B |
| Current assets | $3.50B | $3.28B |
| PP&E, net | $395.72M | $382.88M |
| Goodwill | $8.73B | $9.05B |
| Intangibles | $3.25B | $3.56B |
| Total assets | $16.27B | $16.63B |
| Current liabilities | $3.20B | $2.64B |
| Long-term debt | $2.87B | $3.40B |
| Total debt | $2.87B | $3.40B |
| Total liabilities | $7.08B | $7.19B |
| Shareholders' equity | $9.19B | $9.44B |
| Net debt | $2.23B | $2.86B |
| Shares outstanding | 76.57M | 80.76M |
| Cash flow statement | ||
| Operating cash flow | $1.04B | $1.29B |
| Capital expenditure | $174.21M | $168.06M |
| Free cash flow | $861.99M | $1.12B |
| Investing cash flow | -$187.53M | -$266.79M |
| Financing cash flow | -$771.26M | -$837.18M |
| Depreciation & amortization | $383.00M | $488.50M |
| Stock-based compensation | $102.04M | $45.87M |
| Share buybacks | $750.00M | $500.00M |
Free plan shows the latest 2 periods; Pro shows all 18 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.